Biotech

All Articles

2 cancer biotechs merge, developing global footprint

.OncoC4 is taking AcroImmune-- as well as its internal professional manufacturing functionalities-- ...

Amgen files very first phase 3 gain for $400M dermatitis medication

.Amgen has actually discussed (PDF) the very first period 3 data on its own $400 thousand chronic ec...

Biogen, UCB file period 3 lupus succeed after stopping working earlier trial

.Biogen as well as UCB's rely on advancing in to period 3 astride an unsuccessful research study tri...

Aptadir hopes brand-new RNA preventions can easily reverse tricky cancers cells

.Italian biotech Aptadir Therapeutics has launched along with the assurance that its pipe of preclin...

Wave surfs DMD excellence to regulators' doors, sending out stock up

.Surge Lifestyle Sciences has actually met its goal in a Duchenne muscle dystrophy (DMD) study, plac...

Sanofi plucks new CSO from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is going back to the pharma fold, taking up the ...

Achilles splashes tissue treatment program, bandages for cutbacks after skipping 'business viability' objectives

.Achilles Rehabs has actually destroyed its strategy. The British biotech is quiting working on its ...

Aligos heralds phase 2 MASH win, reducing liver fat as much as 46%

.Aligos Therapies is trumpeting a midstage gain in metabolic-dysfunction affiliated steatohepatitis ...

Basilea credit ratings $268M BARDA backing for antifungals, anti-biotics

.Basilea Pharmaceutica's work developing new antifungals has actually received a considerable increa...

Capricor offers Europe civil liberties to late-stage DMD treatment for $35M

.Possessing actually gathered up the U.S. liberties to Capricor Rehabs' late-stage Duchenne muscular...